The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial

Steven Thornton; Thomas M Goodwin; Gorm Greisen; Morten Hedegaard; Joan-Carles Arce

doi:10.1016/j.ajog.2009.01.015

The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial

Steven Thornton, Thomas M Goodwin, Gorm Greisen, Morten Hedegaard, Joan-Carles Arce

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

38 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-Jun

Originalsprog	Engelsk
Tidsskrift	American Journal of Obstetrics and Gynecology
Vol/bind	200
Udgave nummer	6
Sider (fra-til)	627.e1-10
ISSN	0002-9378
DOI	https://doi.org/10.1016/j.ajog.2009.01.015
Status	Udgivet - 2009

Bibliografisk note

Keywords: Adult; Double-Blind Method; Female; Gestational Age; Humans; Obstetric Labor, Premature; Oligopeptides; Pregnancy; Receptors, Oxytocin

Adgang til dokumentet

10.1016/j.ajog.2009.01.015

Citationsformater

The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. / Thornton, Steven; Goodwin, Thomas M; Greisen, Gorm et al.
I: American Journal of Obstetrics and Gynecology, Bind 200, Nr. 6, 2009, s. 627.e1-10.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{015671b068a111df928f000ea68e967b,

title = "The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial",

abstract = "OBJECTIVE: The objective of the study was to compare barusiban with placebo in threatened preterm labor. STUDY DESIGN: This was a randomized, double-blind, placebo-controlled, multicenter study. One hundred sixty-three women at 34-35 weeks plus 6 days, and with 6 or more contractions of 30 seconds duration during 30 minutes, cervical length 15 mm or less, and cervical dilatation > 1 and < 4 cm were randomized to a single intravenous bolus of barusiban (0.3, 1, 3, or 10 mg) or placebo. The primary endpoint was percentage of women who did not deliver within 48 hours. RESULTS: None of the barusiban doses reduced the number of uterine contractions compared with placebo. There was no significant difference in the percentage of women who did not deliver within 48 hours (72% placebo and 65-88% barusiban groups; P = .21-.84). Barusiban was not associated with an adverse safety profile in the woman, fetus, neonate, or infant. CONCLUSION: An intravenous bolus of barusiban was no more effective than placebo in stopping preterm labor in pregnant women at late gestational age.",

author = "Steven Thornton and Goodwin, {Thomas M} and Gorm Greisen and Morten Hedegaard and Joan-Carles Arce",

note = "Keywords: Adult; Double-Blind Method; Female; Gestational Age; Humans; Obstetric Labor, Premature; Oligopeptides; Pregnancy; Receptors, Oxytocin",

year = "2009",

doi = "10.1016/j.ajog.2009.01.015",

language = "English",

volume = "200",

pages = "627.e1--10",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "6",

}

TY - JOUR

T1 - The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial

AU - Thornton, Steven

AU - Goodwin, Thomas M

AU - Greisen, Gorm

AU - Hedegaard, Morten

AU - Arce, Joan-Carles

N1 - Keywords: Adult; Double-Blind Method; Female; Gestational Age; Humans; Obstetric Labor, Premature; Oligopeptides; Pregnancy; Receptors, Oxytocin

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: The objective of the study was to compare barusiban with placebo in threatened preterm labor. STUDY DESIGN: This was a randomized, double-blind, placebo-controlled, multicenter study. One hundred sixty-three women at 34-35 weeks plus 6 days, and with 6 or more contractions of 30 seconds duration during 30 minutes, cervical length 15 mm or less, and cervical dilatation > 1 and < 4 cm were randomized to a single intravenous bolus of barusiban (0.3, 1, 3, or 10 mg) or placebo. The primary endpoint was percentage of women who did not deliver within 48 hours. RESULTS: None of the barusiban doses reduced the number of uterine contractions compared with placebo. There was no significant difference in the percentage of women who did not deliver within 48 hours (72% placebo and 65-88% barusiban groups; P = .21-.84). Barusiban was not associated with an adverse safety profile in the woman, fetus, neonate, or infant. CONCLUSION: An intravenous bolus of barusiban was no more effective than placebo in stopping preterm labor in pregnant women at late gestational age.

AB - OBJECTIVE: The objective of the study was to compare barusiban with placebo in threatened preterm labor. STUDY DESIGN: This was a randomized, double-blind, placebo-controlled, multicenter study. One hundred sixty-three women at 34-35 weeks plus 6 days, and with 6 or more contractions of 30 seconds duration during 30 minutes, cervical length 15 mm or less, and cervical dilatation > 1 and < 4 cm were randomized to a single intravenous bolus of barusiban (0.3, 1, 3, or 10 mg) or placebo. The primary endpoint was percentage of women who did not deliver within 48 hours. RESULTS: None of the barusiban doses reduced the number of uterine contractions compared with placebo. There was no significant difference in the percentage of women who did not deliver within 48 hours (72% placebo and 65-88% barusiban groups; P = .21-.84). Barusiban was not associated with an adverse safety profile in the woman, fetus, neonate, or infant. CONCLUSION: An intravenous bolus of barusiban was no more effective than placebo in stopping preterm labor in pregnant women at late gestational age.

U2 - 10.1016/j.ajog.2009.01.015

DO - 10.1016/j.ajog.2009.01.015

M3 - Journal article

C2 - 19306963

SN - 0002-9378

VL - 200

SP - 627.e1-10

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 6

ER -